Euro Tech Provides Update on Status under Holding Foreign Companies Accountable Act

PR Newswire


HONG KONG
, May 27, 2022 /PRNewswire/ — Euro Tech Holdings Company Limited (Nasdaq: CLWT) (“Euro Tech” or the “Company”) today provides an update on its status under the Holding Foreign Companies Accountable Act (the “HFCAA”).

The Company is aware that it has been provisionally identified by the United States Securities and Exchange Commission (the “SEC”) under the HFCAA as a Commission-Identified Issuer on May 20, 2022, following the Company’s filing of its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the SEC on May 16, 2022.

The Company understands the SEC made such identification pursuant to the HFCAA and its implementation rules issued thereunder, and this indicates that the SEC determines that the Company has retained a registered public accounting firm whose working paper cannot be inspected or investigated completely by the Public Company Accounting Oversight Board of the United States (the “PCAOB”) to issue the audit opinion for its financial statements for the fiscal year ended December 31, 2021.

In accordance with the HFCAA, the securities of a company will be delisted from a U.S. stock exchange if such company has been identified by the SEC for three consecutive years due to PCAOB’s inability to inspect or investigate the registered public accounting firm’s working paper completely.

The Company will continue to monitor market developments and explore possible solutions. The Company will continue to comply with applicable laws and regulations in both China and the United States, and strive to maintain its listing status on Nasdaq.

About Euro Tech Holdings Company Limited

Euro Tech is a premium distributor and manufacturer of high-quality technology instruments as well as an environmental engineering services provider. To meet the environmental needs of the China market, Euro Tech is focusing on the environmental protection for air, water and energy, for which the company can supply monitoring instruments, analytical instruments and testing equipment. Euro Tech’s primary goal is to provide high-quality yet competitively priced instruments and engineering services to the Chinese marketplace. More information on the Company can be found at http://www.euro-tech.com/en/default.asp

Forward Looking Statements

This press release contains forward-looking statements that are made under the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s beliefs and assumptions and on information currently available to the Company’s management. Forward-looking statements include statements regarding the Company’s ability to file its Annual Report for the year ended December 31, 2021. The Company’s actual results and the timing of events could materially differ from those anticipated in such forward-looking statements as a result of certain risks and uncertainties including those described in more detail in the Company’s most recent Annual Report on Form 20-F and other documents on file with the Securities and Exchange Commission, each of which can be found on the SEC’s website, www.sec.gov. Except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Cision View original content:https://www.prnewswire.com/news-releases/euro-tech-provides-update-on-status-under-holding-foreign-companies-accountable-act-301556498.html

SOURCE EURO TECH HOLDINGS COMPANY LIMITED

Renovare Environmental Announces Receipt of Nasdaq Notification Letter

PR Newswire


CHESTNUT RIDGE, N.Y.
, May 27, 2022 /PRNewswire/ — Renovare Environmental, Inc. (Nasdaq: RENO; “Renovare” or “the Company”) announced today that it received notice from Nasdaq on May 24, 2022 stating that the Company was not in compliance with the rules for continued listing, Rule 5250(c)(1), because it has not timely filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022.

As the Company reported in its Form 12b-25 filed with the SEC, the Company could not file its Quarterly Report on Form 10-Q for the three month period ended March 31, 2022 on or prior to the filing deadline due to the fact that certain amounts required further confirmation and analysis. The Company continues to work diligently to conclude the review and will file the Form 10-Q as soon as practicable. The Notification Letter has no immediate effect on the listing of the Company’s common stock on the Nasdaq.

Until the Company regains compliance, quotation information for the Company’s common stock will include an indicator of the Company’s non-compliance.  As previously disclosed, the Company previously had a hearing before Nasdaq at which time the Company submitted a plan to regain compliance with other delisting notices. If the Company does not regain compliance within the time provided by the Staff for this and other requirements, the Company’s securities will be delisted from Nasdaq.

About Renovare Environmental, Inc.

Renovare Environmental, Inc. (Nasdaq: RENO), formerly BioHiTech Global, Inc., is a technology services company providing cost-effective solutions that improve environmental outcomes. Its solutions for waste management include the biological disposal of food waste, and proprietary real-time data analytics tools to reduce food waste generation. When used individually or in combination, our solutions lower the carbon footprint associated with organic waste transportation and can reduce or virtually eliminate landfill usage. Our unique solutions enable businesses and municipalities of all types, as well as educational and governmental facilities to solve everyday problems in a smarter and more cost-effective way while reducing their impact on the environment.

Cautionary Statement Regarding Forward-Looking Statements

The statements in this release include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, those including such words as “anticipates,” “believes,” “remains,” “will,” and the negatives thereof or other comparable terminology, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements also include other passages that are relevant to expected future events, performances, and actions or that can only be fully evaluated by events that will occur in the future. Forward-looking statements in this release include, without limitation, the Company’s statements regarding its business prospects, its expectations and its and others’ actions with respect to the investigation and related matters, expected financial condition and results. There are many factors, risks and uncertainties that could cause actual results to differ materially from those predicted or projected in forward-looking statements including, but not limited to, the findings of the investigation, accountants and other third parties, finalization of its financial statements and controls review, and factors, risks, and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission.

For More Information: 
Please visit: 
www.renovareenv.com

Company Contact:
Renovare Environmental, Inc.
O: 888.876.9300
E: [email protected]

Investors: 

[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/renovare-environmental-announces-receipt-of-nasdaq-notification-letter-301556850.html

SOURCE Renovare Environmental, Inc.

SSR MINING ANNOUNCES VOTING RESULTS FROM 2022 ANNUAL MEETING OF SHAREHOLDERS

PR Newswire


DENVER
, May 27, 2022 /PRNewswire/ – SSR Mining Inc. (NASDAQ: SSRM) (TSX: SSRM) (ASX: SSR) (“SSR Mining” or the “Company”) announces that each of the eight nominees listed in the proxy statement for the 2022 Annual Meeting of Shareholders (the “Meeting”) were elected as directors of SSR Mining on Friday, May 27, 2022. Voting results for the election of directors are set out below:


Nominee Name


Votes For 


% For  


Votes Withheld  


% Withheld  

A.E. Michael Anglin                                       

145,722,299

95.68

6,580,547

4.32

Rod Antal

152,060,790

99.84

250,790

0.16

Thomas R. Bates, Jr.                                          

150,810,200

99.01

1,501,380

0.99

Brian R. Booth

151,666,992

99.58

644,588

0.42

Simon A. Fish

132,891,748

87.25

19,411,098

12.75

Leigh Ann Fisher

151,937,352

99.75

374,229

0.25

Alan P. Krusi

146,484,811

96.18

5,818,035

3.82

Kay Priestly 

148,166,552

97.28

4,136,295

2.72

At the Meeting, the shareholders of SSR Mining also approved: (i) a non-binding advisory resolution to set one year as the frequency of the Company’s future advisory votes on executive compensation; (ii) a non-binding advisory resolution accepting the Company’s approach to executive compensation; (iii) a resolution approving the Company’s 2022 Employee Share Purchase Plan; and (iv) the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.

The voting results for each resolution are set out below:



1 Year 



% 1 Year  



2 Year  



% 2 Years  



3 Year  



% 3 Years  

Advisory Vote on Frequency
of Future Advisory Votes on
Executive Compensation        

146,346,359

96.16

72,633

0.05

5,281,324

3.47

 



Votes For  



% For  



Votes Against  



% Against  

Advisory Vote on Executive
Compensation                                                 

141,900,724

93.16

10,131,592

6.65

Approval of Employee Share
Purchase Plan

151,723,990

99.61

361,223

0.24



Votes For  



% For   



Votes Withheld  



% Withheld  

Appointment of Auditor 

147,373,576

90.08

16,223,655

9.92


About SSR Mining

SSR Mining Inc. is a leading, free cash flow focused gold company with four producing operations located in the USA, Turkey, Canada, and Argentina, combined with a global pipeline of high-quality development and exploration assets. In 2021, the four operating assets produced approximately 794,000 gold-equivalent ounces. SSR Mining is listed under the ticker symbol SSRM on the NASDAQ and the TSX, and SSR on the ASX.


SSR Mining Contacts:

F. Edward Farid, Executive Vice President, Chief Corporate Development Officer
Alex Hunchak, Director, Corporate Development and Investor Relations

SSR Mining Inc.
E-Mail: [email protected]
Phone: +1 (416) 306-5789

To receive SSR Mining’s news releases by e-mail, please register using the SSR Mining website at www.ssrmining.com.

Cision View original content:https://www.prnewswire.com/news-releases/ssr-mining-announces-voting-results-from-2022-annual-meeting-of-shareholders-301556970.html

SOURCE SSR Mining Inc.

Rivian Founder and CEO RJ Scaringe to Participate in Bernstein’s 38th Annual Strategic Decisions Conference

Rivian Founder and CEO RJ Scaringe to Participate in Bernstein’s 38th Annual Strategic Decisions Conference

IRVINE, Calif.–(BUSINESS WIRE)–
On Thursday, June 2, 2022, at 3:30pm ET / 12.30pm PT Rivian’s founder and CEO RJ Scaringe will participate in Bernstein’s 38th Annual Strategic Decisions Conference.

A live webcast of the fireside chat will be available here.

About Rivian:

Rivian exists to create products and services that help our planet transition to carbon neutral energy and transportation. Rivian designs, develops, and manufactures category-defining electric vehicles and accessories and sells them directly to customers in the consumer and commercial markets. Rivian complements its vehicles with a full suite of proprietary, value-added services that address the entire lifecycle of the vehicle and deepen its customer relationships. Learn more about the company, products, and careers at rivian.com.

Investor Contact

[email protected]

Media Contact

Amy Mast: [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Other Automotive Automotive Alternative Vehicles/Fuels

MEDIA:

Logo
Logo

Raytheon Missiles & Defense awarded $624 million for Stinger missile production

PR Newswire


TUCSON, Ariz.
, May 27, 2022 /PRNewswire/ — Raytheon Missiles & Defense, a Raytheon Technologies (NYSE: RTX) business, was awarded a $624 million U.S. Army contract to produce 1,300 Stinger® missiles. The contract includes provisions for engineering support, as well as the test equipment and support needed to address obsolescence, modernize key components, and accelerate production.

“We’re aligned with the U.S. Army on a plan that ensures we fulfill our current foreign military sale order, while replenishing Stingers provided to Ukraine and accelerating production,” said Wes Kremer, president of Raytheon Missiles & Defense. “The funding will be used to enhance Stinger’s producibility in an effort to meet the urgent need for replenishment.”

The combat-proven Stinger missile is a lightweight, self-contained air defense system that can be rapidly deployed by ground troops. Its supersonic speed, agility and highly accurate guidance and control system give the weapon an operational edge against cruise missiles and all classes of aircraft.

The contract is being funded from the Ukraine Supplemental, which contains emergency funding to support Ukrainian defense forces. Raytheon Missiles & Defense continues to work closely with the U.S. Army and its supplier partners to rapidly support the growing demand for Stinger.

About Raytheon Technologies
Raytheon Technologies Corporation is an aerospace and defense company that provides advanced systems and services for commercial, military and government customers worldwide. With four industry-leading businesses ― Collins Aerospace, Pratt & Whitney, Raytheon Intelligence & Space and Raytheon Missiles & Defense ― the company delivers solutions that push the boundaries in avionics, cybersecurity, directed energy, electric propulsion, hypersonics, and quantum physics. The company, formed in 2020 through the combination of Raytheon Company and the United Technologies Corporation aerospace businesses, is headquartered in Waltham, Massachusetts.

Media Contact

Carolyn Beaudry

[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/raytheon-missiles–defense-awarded-624-million-for-stinger-missile-production-301556968.html

SOURCE Raytheon Technologies

GreenPower Announces Results of Annual General and Special Meeting and Appointment of Officers

PR Newswire


VANCOUVER, BC
, May 27, 2022 /PRNewswire/ — GreenPower Motor Company Inc. (NASDAQ: GP) (TSXV: GPV) (the “Company”), a leading manufacturer and distributor of zero-emission, electric-powered, medium and heavy-duty vehicles, announces the results of the Annual General and Special Meeting (AGM) that was held yesterday.

The shareholders elected all of management’s director nominees being Mark Achtemichuk, Fraser Atkinson, Malcolm Clay, Cathy McLay, David Richardson and Brendan Riley.

The shareholders also approved the Company’s Equity Incentive Plan and the appointment of Crow MacKay LLP, Chartered Professional Accountants as the Company’s auditors for the ensuing fiscal year.

Following the AGM the Directors of the Company appointed the following officers of the Company for the ensuing year:  Fraser Atkinson – Chairman and Chief Executive Officer, Brendan Riley – President and Michael Sieffert – Chief Financial Officer and Corporate Secretary.


Contacts


Fraser Atkinson

CEO
(604) 220-8048

Megan Kathman

Skyya PR for GreenPower
(651) 785-3212
[email protected] 


About GreenPower Motor Company Inc.

GreenPower designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo van, and a cab and chassis. GreenPower employs a clean-sheet design to manufacture all-electric vehicles that are purpose built to be battery powered with zero emissions while integrating global suppliers for key components. This OEM platform allows GreenPower to meet the specifications of various operators while providing standard parts for ease of maintenance and accessibility for warranty requirements. GreenPower was founded in Vancouver, Canada with primary operational facilities in southern California. Listed on the Toronto exchange since November 2015, GreenPower completed its U.S. IPO and NASDAQ listing in August 2020. For further information go to www.greenpowermotor.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. © 2022 GreenPower Motor Company Inc. All rights reserved.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/greenpower-announces-results-of-annual-general-and-special-meeting-and-appointment-of-officers-301556964.html

SOURCE GreenPower Motor Company

Allarity Therapeutics Reports First Quarter 2022 Financial Results

Cambridge, MA U.S.A. (
May
27
,
2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today reported financial results for the first quarter ended March 31, 2022.

F
irst
Quarter Financial Results

Balance Sheet: As of March 31, 2022, Allarity’s cash was $14.5 million, as compared to $19.6 million as of December 31, 2021.

R&D Expenses: Research and Development (R&D) expenses were $1.3 million for the three months ended March 31, 2022, compared to $1.3 million for the quarter ended March 31, 2021.

Impairment of Intangible Assets
: Impairment of Intangible Assets was $14.0 million for the three months ended March 31, 2022, compared to nil for the quarter ended March 31, 2021.

G&A Expenses: General and Administrative (G&A) expenses were $3.0 million for the three months ended March 31, 2022, as compared to $1.2 million for the three months ended March 31, 2021.

Net Loss: Net loss was $3.1 million for the three months ended March 31, 2022, compared to $3.1 million for the comparable period in 2021.

About
Allarity
Therapeutics

Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP® platform. The Company has a mature portfolio of five drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer; dovitinib, a post-Phase 3 pan-tyrosine kinase inhibitor; IXEMPRA® (Ixabepilone), a microtubule inhibitor approved in the U.S. for the treatment of second-line metastatic breast cancer and in Phase 2 development in Europe for the same indication; and 2X-111, a liposomal formulation of doxorubicin in Phase 2 development for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured out-license to Smerud Medical Research International AS. LiPlaCis®, a liposomal formulation of cisplatin and its accompanying DRP® is being developed via a partnership with Chosa ApS, an affiliate of Smerud Medical Research International, for late-stage metastatic breast cancer. The Company is headquartered in the United States and maintains an R&D facility in Hoersholm, Denmark. For more information, please visit the Company’s website at www.Allarity.com

About the Drug Response Predictor – DRP

®

Companion Diagnostic

Allarity uses its drug-specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high DRP® score, the therapeutic response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP® is based on messenger RNA from patient biopsies. The DRP® platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined (both retrospective and prospective), including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA®. The DRP® platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in peer reviewed literature.

Follow
Allarity
on
S
ocial
M
edia

Facebook: https://www.facebook.com/AllarityTx/
LinkedIn: https://www.linkedin.com/company/allaritytx/
Twitter: https://twitter.com/allaritytx

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Allarity’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, all statements under the heading “Anticipated Milestones in 2022,” statements relating to the Company’s NDA submission for dovitinib and its PMA submission for the drug-specific DRP® companion diagnostic for dovitinib, any statements related to ongoing clinical trials for stenoparib for the treatment of advanced ovarian cancer, or ongoing clinical trials (in Europe) for IXEMPRA® for the treatment of metastatic breast cancer, and statements relating to the effectiveness of the Company’s DRP® companion diagnostics platform in predicting whether a particular patient is likely to respond to a specific drug. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the receipt of regulatory approval for dovitinib or any of our other therapeutic candidates or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic candidates, and the risk that the current COVID-19 pandemic will impact the Company’s current and future clinical trials and the timing of the Company’s preclinical studies and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form 10-K for the year ended December 31, 2021 filed today with the Securities and Exchange Commission, available at the Securities and Exchange Commission’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

ALLARITY THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)

ALLARITY THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share amounts)
(unaudited)

###


Company Contact:

        Jens Knudsen
        Chief Financial Officer
        [email protected]

Investor Relations:

        Chuck Padala
        LifeSci Advisors
        +1 (646) 627-8390
        [email protected]
        
U.S. Media Contact:

        Mike Beyer
        Sam Brown, Inc.
        +1 (312) 961-2502
        [email protected]

        
EU Media Contact:

        Thomas Pedersen
        Carrotize PR & Communications
        +45 6062 9390
        [email protected]

Attachment



Akerna Announces Corporate Restructuring

Consolidation, Headcount, and Reductions Expected to Yield Material Annualized Cost Savings, effective July 1, 2022

DENVER, May 27, 2022 (GLOBE NEWSWIRE) — Akerna Corp. (Nasdaq: KERN) (“Akerna”), a leading enterprise software company and developer of one of the most comprehensive technology infrastructures, ecosystems, and compliance engines powering the global cannabis industry, today announced that the Company is implementing a plan to reduce its workforce and operating costs in order to focus its resources, accelerate its path to profitability, and create stakeholder value.

“Our sales performance in 2022 has thus far met our expectations. We believe we are showing signs of progress with revenue now at a run rate of $27m at last filing,” commented Jessica Billingsley, Akerna’s Chief Executive Officer. “While we believe we can continue to grow revenue and continue to reduce expenses over time, we have made the decision to focus our initiatives on our enterprise business and new market expansion of our SMB business, at least until the market conditions and the regulatory environment are in more favorable territory.

“We can see a path to positive cash flows and profitability, and the board and the management team are committed to getting there on an accelerated timetable. While we continue to deal with liquidity concerns, our headcount reduction and additional cost savings measures represent a material annual cost savings. As part of this restructure, executive leadership team has also collectively agreed to a 25% reduction in salary to help support the company’s cost savings initiatives. As we noted on our last earnings call, bookings have been strong and our CARR is $21.1 million, and we are looking to continue to grow our top-line through a combination of enterprise wins as well as the opportunity we see in new market expansion from the SMB side of the business,” added Ms. Billingsley.

The company anticipates reporting $690,000 in total costs in its second quarter of 2022 to implement the reduction in force, including the following cost elements: $630,000 in severance and associated payroll taxes; $40,000 in legal costs; and $20,000 in employee insurance benefits. Of the total cost, $440,000 in salaries, payroll taxes and benefits costs would have been reported in its second quarter if the reduction in force had not been implemented.

Forward-Looking Statements

Certain statements made in this report are “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. Such forward-looking statements include but are not limited to statements regarding our believe that we can continue to grow revenue and reduce costs, our belief that there is a pathway to positive cash flows and profitability, our belief that we can grow our top-line through enterprise wins and expansion into new markets and any statement regarding the future operating results of the Company. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of significant known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside Akerna’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others that may affect actual results or outcomes, include our ability to continue as a going concern given our current liquidity risks and the risks and uncertainties disclosed from time to time in Akerna’s filings with the U.S. Securities and Exchange Commission, including those under the heading “Risk Factors” in the Company’s latest annual report on Form 10-K filed on March 31, 2022 and in its subsequent reports. You are cautioned not to place undue reliance on forward-looking statements. All information herein speaks only as of the date hereof, in the case of information about Akerna, or the date of such information, in the case of information from persons other than Akerna. Akerna undertakes no duty to update or revise the information contained herein.

About Akerna 

Akerna (Nasdaq: KERN) is an enterprise SaaS company focused on compliantly serving the cannabis, hemp, and CBD industry. First launched in 2010, Akerna has tracked more than $30 billion in cannabis sales to date and is the first cannabis software company listed on Nasdaq. Using connected data and information to propel the cannabis industry forward, Akerna empowers businesses, governments, patients, and consumers to make smart decisions.  

The Company’s cornerstone technology, MJ Platform, one of the world’s leading cannabis infrastructure as a service platform, powers retailers, manufacturers, brands, distributors, and cultivators. Akerna also offers a complete suite of professional consulting services and data analytics for businesses as well as solo sciences, Leaf Data Systems, Trellis, Ample Organics, Viridian Sciences and 365 Cannabis.

To be included on the Company’s email distribution list, please sign up at https://ir.akerna.com/news-events/email-alerts

For more information, visit https://www.akerna.com/.

Contacts:

Media

Georgia Jablon ([email protected])

Investor

Peter Seltzberg, 516-419-9915, [email protected]



Closure Due to Limited Interest Since Launch

CHICAGO and MILWAUKEE and NEW YORK, May 27, 2022 (GLOBE NEWSWIRE) —  Due to its inability to attract sufficient investment assets, the Board of Trustees of the Tidal ETF Trust has decided to liquidate and close the iClima Climate Change Solutions ETF (CLMA) (the “Fund”), based on the recommendation of the Fund’s investment adviser, Toroso Investments LLC. As a result, the Board concluded that liquidating and closing the Fund would be in the best interest of the Fund and its shareholders. 

The Fund will cease trading on the NYSE Arca, Inc. (“NYSE”) and will be closed to purchase by investors as of the close of regular trading on the NYSE on June 10, 2022 (the “Closing Date”). The Fund will not accept purchase orders after the Closing Date.

Shareholders may sell their holdings in the Fund prior to the Closing Date and customary brokerage charges may apply to these transactions. However, from June 10, 2022 through June 17, 2022 (the “Liquidation Date”), shareholders may be able to sell their shares only to certain broker-dealers and there is no assurance that there will be a market for the Fund’s shares during this time period. Between the Closing Date and the Liquidation Date, the Fund will be in the process of closing down and liquidating the Fund’s portfolio. This process will result in the Fund increasing its cash holdings and, as a consequence, not tracking its underlying index, which is inconsistent with the Fund’s investment objective and strategy.

On or about the Liquidation Date, the Fund will liquidate its assets and distribute cash pro rata to all shareholders of record who have not previously redeemed or sold their shares, subject to any required withholding. Liquidation proceeds paid to shareholders generally should be treated as received in exchange for shares and will therefore be treated as a taxable event giving rise to a capital gain or loss depending on a shareholder’s tax basis. Shareholders should contact their tax adviser to discuss the income tax consequences of the liquidation. In addition, these payments to shareholders may include distributions of accrued capital gains and dividends. As calculated on the Liquidation Date, the Fund’s net asset value will reflect the costs of closing the Fund. Once the distributions are complete, the Fund will terminate.

ABOUT TIDAL ETF SERVICES

Formed by ETF industry pioneers and thought leaders, Tidal ETF Services LLC sets out to revolutionize the way ETFs have historically been developed, launched, marketed, and sold. With a focus on growing AUM, Tidal offers a comprehensive suite of services, proprietary tools, and methodologies designed to bring lasting ideas to market. Tidal is an advocate for ETF innovation. The firm is on a mission to provide issuers with the intelligence and tools needed to efficiently and to effectively launch ETFs and to optimize growth potential in a highly competitive space. For more information, visit tidaletfservices.com.



MEDIA CONTACT

Eric Falkeis

[email protected]

Momentus First Demonstration Mission Update #1

Momentus First Demonstration Mission Update #1

SAN JOSE, Calif.–(BUSINESS WIRE)–
Momentus Inc. (NASDAQ: MNTS) (“Momentus” or the “Company”), a U.S. commercial space company that plans to offer transportation and other in-space infrastructure services, today announced a status update on its first demonstration mission.

We have established two-way contact with the Vigoride Orbital Transfer Vehicle, and as is often the case with a new spacecraft, have had some initial anomalies. We are using an unplanned frequency as we work through this and are applying for a Special Temporary Authority (STA) with the FCC to address that in order to help command the vehicle back to nominal configuration. Our engineering and operations team is working to address the anomalies.

About Momentus

Momentus is a U.S. commercial space company that plans to offer in-space infrastructure services, including in-space transportation, hosted payloads and in-orbit services. Momentus believes it can make new ways of operating in space possible with its planned in-space transfer and service vehicles that will be powered by an innovative water plasma-based propulsion system that is under development.

Forward-Looking Statements

This press release contains certain statements which may constitute “forward-looking statements” for purposes of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding Momentus or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, and are not guarantees of future performance. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Momentus’ control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to risks and uncertainties included under the heading “Risk Factors” in the Annual Report on Form 10-K filed by the Company on March 9, 2022, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of our website at investors.momentus.space. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Investors

Darryl Genovesi at [email protected]

Media

Jessica Pieczonka at [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Satellite Technology Aerospace Transport Manufacturing Other Technology Other Transport

MEDIA:

Logo
Logo